metronidazole fresenius
fresenius kabi polska sp.z.o.o. - metronidazolas - infuzinis tirpalas - 5 mg/ml - metronidazole
supplin
sandoz gmbh - metronidazolas - plėvele dengtos tabletės - 500 mg - metronidazole
metronidazole b.braun
b.braun melsungen ag - metronidazolas - infuzinis tirpalas - 5 mg/ml - metronidazole
metronidazole vioser
vioser s.a. parenteral solutions industry - metronidazolas - infuzinis tirpalas - 500 mg/100 ml - metronidazole
efloran
krka, d.d., novo mesto - metronidazolas - infuzinis tirpalas - 400 mg; 500 mg/100 ml - metronidazole
supplin
lex ano, uab - metronidazolas - plėvele dengtos tabletės - 500 mg - metronidazole
metronidazol arena
polta, uab - metronidazolas - kapsulės - 500 mg - metronidazole
metronidazol arena
nenurodyta - metronidazolas - kapsulės - 250 mg - metronidazole
metronidazol-bp
polta, uab - metronidazolas - plėvele dengtos tabletės - 500 mg - metronidazole
enhertu
daiichi sankyo europe gmbh - trastuzumab deruxtecan - krūties navikai - antinavikiniai vaistai - breast cancerher2-positive breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-positive breast cancer who have received one or more prior anti-her2-based regimens. her2-low breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy (see section 4. non-small cell lung cancer (nsclc)enhertu as monotherapy is indicated for the treatment of adult patients with advanced nsclc whose tumours have an activating her2 (erbb2) mutation and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy. gastric cancerenhertu as monotherapy is indicated for the treatment of adult patients with advanced her2-positive gastric or gastroesophageal junction (gej) adenocarcinoma who have received a prior trastuzumab-based regimen.